Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer

Inclusion Criteria: * Male or female patients with histologically proven adenocarcinoma of the rectum ,T3/4 or any node positive disease (clinical stage according the TNM classification system) * No evidence of metastatic disease. * Age 18 - 65 years * Kps 80-100 * No prior radiotherapy, chemotherapy or any targeting therapy for rectal cancer * Normal hematological, hepatic and renal function, Ability to swallow tablets * Signed informed consent * Patients must be willing and able to comply with the protocol for duration of the study Exclusion Criteria: * Malignancy of the rectum other than adenocarcinoma * Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin * Significant heart disease (uncontrolled hypertension despite of medication (\> 150/100 mmHg), NYHA class III or IV heart disease,unstable angina or myocardial infarction within the past 1 year prior the study entry, history of significant ventricular arrhythmia requiring treatment) * Evidence of active peptic ulcer or upper GI bleeding * Evidence of bleeding diathesis or coagulopathy * Patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucitosine, phenytoin, or warfarin * Known hypersensitivity to biological drugs * Treatment with any investigational drug within 30 days before beginning treatment with the study drug * Pregnant or lactating patient